Related Experiment Video

Updated: Jul 29, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.6K

Targeting histone deacetylases for heart diseases

Gang Jin1, Kaiyue Wang1, Yaohui Zhao1

  • 1Pharmacy College, Henan University of Chinese Medicine, 450046 Zhengzhou, China.

Bioorganic Chemistry
|May 24, 2023
PubMed

Insights

Histone deacetylase (HDAC) inhibitors show promise for treating heart diseases by regulating gene expression and chromatin. This review explores their therapeutic potential and development challenges.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Histone deacetylases (HDACs) regulate crucial biological functions including gene transcription and chromatin remodeling.
  • Dysregulation of HDACs is implicated in various diseases, notably cancers and cardiovascular diseases.
  • HDAC inhibitors represent a promising therapeutic strategy for cardiac conditions.

Purpose of the Study:

  • To systematically review the therapeutic roles of various HDAC inhibitors in treating heart diseases.
  • To discuss the current opportunities and challenges in developing HDAC inhibitors for cardiovascular applications.

Main Methods:

  • Literature review of studies on HDAC inhibitors and cardiac diseases.
  • Analysis of different chemotypes of HDAC inhibitors.
  • Evaluation of clinical potential and development hurdles.

Main Results:

  • Numerous HDAC inhibitors have demonstrated potential clinical value for cardiac diseases.
  • Different chemotypes of HDAC inhibitors exhibit varied therapeutic effects on the heart.
  • The development of HDAC inhibitors for cardiac conditions faces specific challenges.

Conclusions:

  • HDAC inhibitors offer a promising avenue for the treatment of cardiovascular diseases.
  • Further research and development are needed to overcome challenges and optimize HDAC inhibitor therapy for cardiac conditions.

Keywords:
HDACsHeart diseasesInhibitors

More Related Videos

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

21.4K
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.6K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.4K
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
8.3K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
19
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
17
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K